Welcome to our dedicated page for SS Innovations International SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on SS Innovations International's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into SS Innovations International's regulatory disclosures and financial reporting.
SS Innovations International, Inc. files its annual report describing rapid expansion in surgical robotics focused on making robotic surgery more affordable, especially in India and other underserved markets. The company’s SSi Mantra system has received Indian CDSCO approval, ISO 13485 certification, and additional clearances in multiple countries.
As of December 31, 2025, SSi Mantra had 168 installed systems across 10 countries and was used in 7,885 procedures, most in general surgery and urology, with more than 120 telesurgeries completed over distances up to thousands of miles. On March 6, 2026, the company completed a private placement of 5,774,839 common shares for gross proceeds of $18,621,498 to fund working capital, global growth initiatives, and preparation for U.S. and EU market entry.
SS Innovations International, Inc. completed a private placement of common stock on March 6, 2026, raising approximately $18.6 million in gross proceeds from the sale of 5,774,839 shares.
The company plans to use the net proceeds for working capital and general corporate purposes, including growth initiatives in India and other existing global markets and preparation for entry into the United States and European Union markets. A $2.5 million non-affiliate investment will trigger a $175,000 cash commission and five-year warrants for 41,667 shares at $3.45 per share to a FINRA member firm. The company expects FDA review of its 510(k) for the SSi Mantra system to be completed by mid-2026 and is pursuing European Union CE marking, which it believes it can obtain in 2026.
SS Innovations International, Inc. executive Barry F. Cohen, COO – Americas, reported an insider transaction involving company common stock. He tendered 32,000 shares of common stock at $6.63 per share to a non-affiliated third-party lender in satisfaction of principal and interest on a $200,000 promissory note. Following this stock-for-debt repayment, he continues to hold 7,806,088 common shares directly.
SS Innovations International, Inc. director and Asia Pacific CEO Vishwajyoti Pascual Srivastava reported a bona fide gift transfer of 2,000,000 shares of common stock. The shares were transferred at a price of $0.00 per share and are held indirectly through Matilda Pvt. Ltd., an entity in which he has a controlling interest. Following the transaction, 2,000,000 shares are reported as indirectly owned through Matilda Pvt. Ltd.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 2,000,000 shares of common stock. The transfer was made at a reported price of $0.00 per share and is classified as an indirect transaction through Sushruta Pvt. Ltd., which holds the shares of record. Following this gift transfer, indirect holdings reported for this entity total 109,353,014 shares of common stock.
SS Innovations International, Inc. is offering 11,286,681 shares of common stock, with underwriters holding a 45‑day option to buy up to 1,693,002 additional shares. At an assumed price of $4.43, the company expects net proceeds of about $45.8 million (or $52.8 million with the option fully exercised), to fund working capital, manufacturing expansion, clinical trials and global marketing.
SS Innovations is a commercial-stage surgical robotics company selling its SSi Mantra system, with 168 systems installed across 10 countries and 7,885 procedures performed as of December 31, 2025. The business remains loss-making, with 2024 revenue of $20.65 million and a net loss of $19.15 million, and is seeking FDA 510(k) clearance and EU CE certification. Post‑offering, 205,643,381 shares will be outstanding, and the founder and CEO will still control over 55% of voting power, while risks include ongoing losses, financing needs, heavy regulation, data privacy obligations and possible U.S. tariffs.
SS Innovations International officer Milan Rao, the Global COO and CFO, has filed an initial ownership report showing beneficial ownership of 120,000 shares of common stock. These are restricted shares granted on January 16, 2026 under the company’s 2016 Incentive Stock Plan.
The restricted stock vests in 12 equal monthly installments of 10,000 shares, and each installment requires Rao’s continued service with the company and compliance with the other terms and conditions of the incentive plan.
SS Innovations International, Inc. director and COO - Americas Barry F. Cohen filed an amended Form 4 to correct previously reported ownership details. The amendment relates to a gift of 25,500 shares of common stock on 12/30/2025, reported with transaction code G at a price of $0.00 per share. After this correction, Cohen is shown as beneficially owning 7,838,088 shares of SS Innovations common stock in direct form.
The filing explains that it corrects a prior error where a 3,300 share gift had been inadvertently reported twice and also adjusts the total number of shares held following the reported transactions. This makes the insider ownership record more accurate but does not reflect a new purchase or sale for cash.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava, who is also a director and 10% owner, reported an indirect transaction in the company’s common stock. On 01/19/2026, a transaction coded “G” involved 10,000 shares of common stock at a price of $0.00 per share. After this transaction, 111,353,014 shares of common stock were reported as beneficially owned indirectly, held by Sushruta Pvt. Ltd., an entity in which Srivastava has a controlling interest and which is the holder of record.
SS Innovations International, Inc. insider entity uses shares to repay debt. Chairman and CEO Sudhir Srivastava, a director and 10% owner, reported two indirect transactions on January 17, 2026 involving common stock held by Sushruta Pvt. Ltd., an entity in which he has a controlling interest. Sushruta tendered 800,000 shares of SS Innovations common stock at $2.53 per share to satisfy principal and interest on a $2.0 million promissory note owed to a non‑affiliated third-party lender. On the same date, Sushruta tendered an additional 400,000 shares at $2.522 per share to satisfy principal and interest on a separate $1.0 million promissory note to a non‑affiliated lender. Following these dispositions, Srivastava reported 111,343,014 SS Innovations shares beneficially owned indirectly through Sushruta.